Copyright
©The Author(s) 2024.
World J Gastroenterol. Oct 28, 2024; 30(40): 4339-4353
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4339
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4339
Pathway | Type 1 diabetes | Type 2 diabetes | Type 3 diabetes (Alzheimer’s disease) |
Insulin production | Autoimmune destruction of pancreatic beta cells leads to absolute insulin deficiency | Insulin resistance in peripheral tissues leads to compensatory hyperinsulinemia, followed by beta-cell dysfunction and relative insulin deficiency | Insulin resistance and deficiency in the brain contribute to impaired glucose metabolism and cognitive decline |
Immune system involvement | Autoimmune response targeting beta cells, involving T cell-mediated destruction | Chronic low-grade inflammation contributes to insulin resistance and beta-cell dysfunction | Possible involvement of neuroinflammation and immune dysregulation contributing to neurodegeneration |
Glucose metabolism | Hyperglycemia due to lack of insulin, resulting in impaired glucose uptake by cells | Hyperglycemia due to insulin resistance and inadequate compensatory insulin secretion by beta cells | Impaired glucose metabolism in the brain leads to reduced energy supply and cognitive impairment |
Beta-cell function | Progressive loss of beta-cell mass due to autoimmune attack | Gradual decline in beta-cell function due to chronic insulin resistance, oxidative stress, and inflammation | Not directly related to beta cells, but brain insulin signaling impairment is a key factor |
Associated complications | Ketoacidosis, retinopathy, nephropathy, neuropathy, cardiovascular disease | Retinopathy, nephropathy, neuropathy, cardiovascular disease, non-alcoholic fatty liver disease | Cognitive decline, memory loss, dementia, potential overlap with Alzheimer’s disease |
Therapeutic targets | Insulin replacement therapy, immunomodulation, beta-cell regeneration | Insulin sensitizers, lifestyle modifications, beta-cell support and regeneration, and anti-inflammatory agents | Improving brain insulin sensitivity, neuroprotective agents, and management of cognitive decline |
- Citation: Abdalla MMI. Advancing diabetes management: Exploring pancreatic beta-cell restoration’s potential and challenges. World J Gastroenterol 2024; 30(40): 4339-4353
- URL: https://www.wjgnet.com/1007-9327/full/v30/i40/4339.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i40.4339